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Thromboxane (TX) A2 has been identified as an important intrahepatic vasoconstrictor
upon Kupffer cell (KC) activation during infections such as spontaneous bacterial peri-
tonitis (SBP). The study aimed to investigate the role of TLRs in the TXA2 increase in liver
nonparenchymal cells and their related mechanisms. Here, we identified TLR-2 as a com-
mon pathway for different microbials: microbial lysates including Gram-positive bacteria,
Gram-negative bacteria, and fungi all increased TXA2 secretion via activation of TLR-2
in human KCs, accompanied by increased expression and phosphorylation of Myd88-
related pathway. Of all TLR agonists, only TLR-1, -2, and -4 agonists increased TXA2 in
human KCs. These results were further confirmed by mouse liver nonparenchymal cells.
Comparing the effects of TLR-1, -2, and -4 antagonists, only TLR-2 antagonist showed
inhibitory effects with all tested microbial lysates. Pretreatment with TLR-2 antagonist in
human KCs blocked the secretion of IL-10, CXCL-10, TNF-α, and IL-6 induced by Gram-
positive and Gram-negative bacterial stimulation. IL-23 and IL-1β were only induced by
Gram-negative bacteria. Thus, TLR-2 might be a potential marker and an attractive target
for future treatment of patients with SBP. In addition, IL-23 and IL-1β might distinguish
early between Gram-positive and Gram-negative SBP.
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Introduction
Spontaneous bacterial peritonitis (SBP) is the most common infec-
tion associated with acute-on-chronic liver failure (ACLF), which
is characterized by high morbidity and mortality due to a systemic
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inflammatory response syndrome and subsequent multiple-organ
dysfunction [1]. Gram-negative aerobic organisms such as Kleb-
siella pneumoniae (K. pneumoniae), Escherichia coli (E. coli), and
Enterobacter cloacae (E. cloacae) are the most common cause of
SBP patients, other common organisms include Enterococcus fae-
cium (E. faecium), Streptococcus pneumoniae (S. pneumoniae), and
Staphylococcus aureus (S. aureus), while Candida albicans (C. albi-
cans) is reported as the most common pathogen of spontaneous
fungal peritonitis [2]. Nonparenchymal cells (NPCs), such as Kupf-
fer cells (KCs), sinusoidal endothelial cells (SECs), and hepatic
stellate cells (HSCs), are the first cells to meet bacteria or their
products in the liver [3,4].
Recognition of microorganisms and activation of immune
responses are mediated through pattern recognition receptors
(PRRs), which mainly include toll like receptors (TLRs), NOD-like
receptors (NLRs), RIG-I-like receptors (RLRs), and DNA sensors
such as absent in melanoma 2 (AIM2). The expressions of NOD1,
NOD2 and inflammasome receptors (NLRP1, NLRP3, AIM2)
in non-stimulated liver NPCs are almost undetectable [5]. In
contrast, TLR genes are widely expressed in NPCs: TLR-2 to -5
in HSCs; TLR-2 to -4 in KCs; and TLR-2 to -4 and TLR-9 in SECs.
TLR-2, which can form complexes with TLR-1 or -6, is expressed in
all NPCs but is highest in KCs [5,6]. TLR-2 receptors in monocytes
are significantly overexpressed in patients with tuberculosis, sys-
temic lupus erythematosus, and myelodysplastic syndromes [7,8].
The synergistic effects of the inflammasome (the heterogeneous
group of multiprotein complexes) and TLR signals are the main
causes for cytokine release. Activation of inflammasome can cause
autocatalysis and kinase activation, leading to the maturation
of proinflammatory cytokines [9]. Once activated by microbial
antigens, inflammasome and TLR signal transduction become
activated through Myd88 and MAPK resulting in the translocation
of NF-κB with subsequent induction of inflammatory cytokines
[10-12].
Besides inflammatory cytokines, thromboxane (TX) A2 has
been recently identified as an important factor of bacterial defense
and the progression of ACLF [3]. TXA2, mainly secreted by KCs in
the liver, is an important vasoconstrictor and plays a crucial role in
intrahepatic vascular constriction, platelet activation, and aggre-
gation [13]. TXA2 can be upregulated by non-alcoholic fatty liver
disease, ischemia, and inflammation in in vitro and in vivo exper-
iments [14]. In patients, increased TXA2 synthesis was also linked
to infections, acute myocardial ischemia, and heart failure [15].
The pathophysiology of KC activation and the function of TXA2
to increase portal perfusion pressure following TLR agonist stim-
ulations have been well investigated in our previous publications
[3,4,16]. However, which TLRs on KCs are responsible for the
TXA2 secretion caused by bacterial infections remained unclear.
In this study, KCs isolated from human and mouse liver tissues
were stimulated by microbial lysates derived from cultured isolates
of SBP patients. By investigating the effects of TLR antagonists in
combination with different microbial lysates, we aimed to identify
the individual receptors and cascades of bacterial-induced increase
in TXA2. Besides, we compared the differences in inflammatory
cytokine profiles induced by different types of microorganisms.
Results
Microbial lysates induced TXB2 secretion in KCs
CD163, CD68, and CD11b are exclusively expressed on
macrophages and are often used to identify macrophages in tis-
sue sections such as KCs. Immunostaining results showed positive
cells with typical morphological characteristics in both human and
mouse KCs (Fig. 1A–C), verifying those isolated cells were our tar-
get cells.
According to our dose-response experiments (Supporting
Information Fig. S1), 8 μg/mL microbial lysates were chosen to
stimulate primary KCs. Lysates of Gram-negative bacteria (GNB,
including K. pneumoniae, E. coli, and E. cloacae), Gram-positive
bacteria (GPB, including E. faecium, S. pneumoniae, and S. aureus)
and C. albicans all significantly increased Thromboxane B2 (TXB2,
the stable degradation product of TXA2) TXB2 secretion in both
human and mouse KCs (Fig. 1D and E).
TLR-1, -2, and -4 agonists increased TXB2
secretion in KCs
TLR-1 to -9 agonists (names and related dosages were described
below) were then used to investigate the effective TLRs increas-
ing TXB2 in KCs. Twenty-four hour stimulation with Pam3CSK4,
heat-killed Listeria monocytogenes (HKLM) or LPS increased TXB2
secretion in both human and mouse KCs (Fig. 2A and B). The
same concentrations of TLR-1 to -9 agonists treating primary KCs
were also tested in mouse SECs and HSCs. TLR agonists had no
effects on TXB2 secretion in SECs (Fig. 2C). Interestingly, an over-
all reduction was observed in HSCs after TLR agonists’ stimulation
and significant reduction of TXB2 was found by applying TLR-3,
-5, and -9 agonists (Fig. 2D).
TLR-2 antagonist showed the strongest effect in
reducing bacterial-induced TXB2 increase
According to the results above, TLR-1, -2, and -4 seemed to be
most possibly related to bacterial-induced TXB2 increase in KCs.
CU-CPT22 (10 μM), 1 μg/mL Mab-mTLR2, and 1 μM TAK242
selected by dose-response experiments (Supporting Information
Fig. S2) were used as antagonists for TLR-1, -2, and -4 in the
following experiments.
Antagonists were added to human KCs 1 h before microbial
stimulation. TXB2 increase caused by K. pneumoniae, E. coli, E.
cloacae, E. faecium, and S. pneumoniae were attenuated by TLR-1,
-2, or -4 antagonists (Fig. 3A–E). TLR-1 and -2 antagonists also
reduced TXB2 secretion by S. aureus (Fig. 3F). Only Mab-mTLR2
decreased C. albicans-induced TXB2 production (Fig. 3G). Com-
paring among TLR-1, -2, and -4 antagonists, Mab-mTLR2 seemed
to be the most effective antagonist.
The effects of combined TLR antagonists were also compared
with each single substance. Either single TLR-1, -2, and -4
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Figure 1. Stimulation with microbial lysates increased TXB2 secretion in KCs. (A–C) Anti-CD163 (red), CD68 (green), and CD11b (yellow) antibodies
were used to confirm the primary KCs isolated from human tissues and mice and the nuclei was stained with DAPI (blue), each picture was
representative from three separate immunostaining results; (blue color represents DAPI and scale bar represents 100 μm; 200× magnification). (D
and E) 8 μg/mL microbial lysates including K. pneumoniae, E. coli, E. cloacae, E. faecium, S. pneumoniae, S. aureus, and C. albicans were used to stimulate
primary KCs isolated from human or mice tissues. 24 h stimulation with each microbial lysates significantly (*p < 0.05, **p < 0.01, ***p < 0.001,
comparing between values before and after stimulation, two-sided Student’s t-test) increased TXB2 secretion in human KCs (D) and mouse KCs
(E). TXB2 was measured by ELISA as detailed in the Materials and Methods section. Data are expressed as mean ± SD, n = 6 samples, and are from
three independent experiments with a total of three human tissue or 12 mice.
antagonists or combined substances significantly decreased TXB2
concentrations after GNB activation. In addition, combined
substance achieved a better effect than any single substances
(Supporting Information Fig. S3).
Myd88 related pathway is essential for
bacterial-induced TXB2 increase
Myd88-related pathways were reported to be involved in the TXB2
secretion. Due to the limited number of primary KCs, THP-1 cells
(the most commonly used macrophage-like cell line with similar
TLR protein expression to human KCs [5]) were used to replace
KCs. We treated THP-1 cells with the same dose and time of micro-
bial lysate, and detected the expression of Myd88 related pathway
proteins. Compared with the control group (cells without stimu-
lants), Myd88 expression and phosphorylation levels of MAPK and
NF-κB increased after stimulation with TLR-2 agonists or microbial
lysates. In addition, the expression of phosphorus-MAPK and NF-
kB caused by GNB were higher than those caused by GPB (Fig. 4).
Effect of TLR-2 antagonist on the secretion of
inflammatory cytokines
The inflammatory cytokine secretion by KCs via the Myd88
pathway is an important mechanism during bacterial infections.
Twenty-four hour stimulation with GPB products significantly
increased the secretion of IL-10, CXCL-10, TNF-α, and IL-6 in
human KCs. Thereby, all the cytokine levels could be reduced
by Mab-mTLR2 pretreatment (Fig. 5A–D). Besides the cytokines
above, GNB also increased IL-1β and IL-23 secretion. The TLR-
2 antagonist decreased the levels of IL-10, CXCL-10, IL-1β, and
IL-23 among all six effective cytokines (Fig. 5A–F). C. albicans
only induced TNF-α and IL-6 secretion and TNF-α increase can be
blocked by TLR-2 antagonists (Fig. 5C and D). None of the micro-
bial lysates had significant effects in IL-1RA or IL-12p70 (Fig. 5E
and F).
Effects of purinergic signaling in the bacterial-induced
TXB2 increase
In addition to the TLR signal, purinergic signaling is also involved
in the inflammatory immune response in the liver. Subtypes
including type 2 P (P2Y) G protein-coupled receptors and P2X
ATP-gated cation channels are widely expressed in hepatocytes
and NPCs [17, 18]. P2 × 1R and P2 × 7R were reported to be
expressed in KCs, the expression of P2 × 7R was increased during
microbial stimulation while P2 × 1R showed no significant change
(Supporting Information Fig. S4A and B). Furthermore, a P2 × 7R
antagonist inhibited the effect of both GPB and GNB, confirming
the role of P2 × 7R in bacterial-induced TXB2 secretion in human
C© 2020 The Authors. European Journal of Immunology published by
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Figure 2. TLR-1, -2, and -4 agonists increased TXB2 secretion in KCs. The same doses of special TLR-1 to -9 agonists were used in human KCs,
mouse KCs, mouse SECs, and mouse HSCs for 24 h. (A and B) Among all ten kinds of agonists, only Pam3CSK4 (0.1 μg/mL), HKLM (10 × 108
cells/mL), and LPS-EK (10 ng/mL) significantly (*p < 0.05, **p < 0.01, ***p < 0.001, comparing between values before and after stimulation, two-sided
Student’s t-test) increased TXB2 secretion in human KCs (A) and mouse KCs (B). (C) None of TLR agonists significantly increased TXB2 secretion
in mouse SECs. (D) An overall reduction was observed in mouse HSCs after TLR agonists’ stimulation. Furthermore, Poly(I:C)-HMW (10 ng/mL),
Poly(I:C)-LMW (10 ng/mL), ST-FLA (10 ng/mL), and ODN1826 (5 μM) induced significant (*p < 0.05, ***p < 0.001, comparing between values before
and after stimulation, two-sided Student’s t-test) effects. TXB2 was measured by ELISA as detailed in the Materials and Methods section. Data are
expressed as mean ± SD, n = 6 samples, and are from three independent experiments with a total of three human tissue or 12 mice.
KCs (Supporting Information Fig. S4E). Although inhibitors of
P2Y1R could block TXA2 production by human platelets [10], the
expression of P2Y1R and P2Y2R in human KCs was too low to be
detected (Supporting Information Fig. S4C and D).
Discussion
Our study is the first to reveal the increase of the vasoconstric-
tor TXA2 after the activation of human KCs with different human
microbial lysates. TXA2 has been identified as a highly relevant
vasoconstrictor in the liver [3,4]. This present study investigated
the role of TLRs in microbial-induced TXA2 increase in liver non-
parenchymal cells (NPCs), its related mechanisms, and the rela-
tionship of inflammatory cytokines to different kinds of microor-
ganisms. Novel findings in the present study were: (1) GPB, GNB,
and fungal lysates, all extracted from SBP patients increased TXB2
secretion in human KCs, with the increased expression and phos-
phorylation of MAPK and NF-κB; (2) SECs and HSCs did not pro-
duce TXB2 after TLR activation, while KCs did; (3) only TLR-1/2,
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Figure 3. Effects of TLR-1, -2, and -4 antagonists differed in different kinds of microbial lysates. Human KCs were treated with the same concen-
tration of TLR-1, -2, or -4 antagonist (CU-CPT22, Mab-mTLR2, or TAK242) for 1 h, and then stimulated with different microbial lysates for 24 h,
including K. pneumoniae, E. coli, E. cloacae, E. faecium, S. pneumoniae, S. aureus, and C. albicans (8 μg/mL each). One hour pretreatment with CU-CPT22
(10 μM), Mab-mTLR2 (1 μg/mL), or TAK242 (1 μM) in human KCs respectively attenuated TXB2 increase caused by K. pneumoniae (A), E. coli (B), E.
cloacae (C), E. faecium (D), and S. pneumoniae (E). Cu-CPT22 and Mab-mTLR2 also decreased TXB2 induced by S. aureus (F). Only Mab-mTLR2 had
effects on C. albicans-induced TXB2 increase (G). The solvent treatment group (Vehicle group) used as a positive control. Data are expressed as
mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 (two-sided Student’s t-test) compared to the positive control. TXB2 was measured by ELISA as detailed
in the Materials and Methods section. Data are expressed as mean ± SD, n = 6 samples, and are from three independent experiments with a total
of three human tissue or 12 mice.
-2, and -4 agonists increased TXB2 secretion in KCs among all TLR
agonists; (4) TLR-2 antagonists showed the most effective reduc-
tion in microbial induced TXB2 secretion compared with TLR-1
and -4 antagonists, combination of TLR-1, -2, and -4 antagonists
attained even better effects; and (5) TLR-2 antagonists attenu-
ated all inflammatory cytokines induced by GPB and partially
cytokines induced by GNB. IL-1β and IL-23 might help to dis-
tinguish between GPB and GNB infections.
The seven most common pathogens extracted from SBP
patients all increased TXB2 secretion in human and mouse KCs
(Fig. 1). The relation between TXB2 production and TLRs espe-
cially TLR-2 and -4 via Myd88 related pathway has been proven
in human alveolar macrophages, peritoneal macrophages, and
various in vivo experiments [19]. According to results involving
TLR -1 to -9 agonists in human and mouse KCs (Fig. 2A and
B), TLR-1, -2, and -4 were identified as the most relevant TLRs
in this process. The increased phosphorylation MAPK and NF-κB
in human KCs following stimulation with microbial lysates also
supported the role of TLRs in microbial-induced TXB2 increase
in human KCs (Fig. 4). Western Blot for THP-1 cells could give
first support for the postulated NF-kB/MAPK pathway. In addi-
tion to THP-1 cells, the NF-κB and MAPK phosphorylation lev-
els in LPS-stimulated peritoneal macrophages and RAW 264.7
macrophages infected with S. aureus also increased [20,21]. Alve-
olar macrophages isolated from LPS-treated mice also showed a
higher ratio of phosphorus-NF-kB/ NF-kB that confirmed the rela-
tion between TLR-2/4 and MAPK/ NF-kB phosphorylation [22].
Previous studies have shown that TLR activation can regulate COX-
1 and COX-2 through the MyD88-dependent NF-κB pathway, and
cause changes in vasoactive factors such as Prostaglandin (PG)
[23]. In our previous research, TXA2 synthase inhibitors and COX-
1 specific inhibitors can reduce TXB2 secretion of KCs caused by
Zymosan (an agonist of TLR-2 and -6), but COX-2 inhibitors do
not have this effect [16]. Combined with the effects of TLR antag-
onists on KCs, we speculate that TLR-1, -2, and -4 activate MyD88-
dependent pathways to regulate COX-1 is the main mechanism by
which bacteria stimulate KCs to secrete TXA2.
TLR-2 has a unique ability to heterodimerize with TLR-1 and
-6. However, TLR2/1 agonists, but not TLR2/6 increased TXB2 in
human KCs consistent with previous results from studies involving
platelets [10]. In unstimulated KCs, the ratio of expression levels
of mRNA for TLR1, TLR2, and TLR6 was approximately 10:40:1
[24]. That may explain why both TLR-1/2 and TLR-2 agonists
increased TXB2 secretion while the TLR-6/2 agonist failed.
The effects of TLR agonists were also confirmed in mouse
NPCs. Mouse KCs showed the same results as human cells after
bacterial stimulation, confirming the results obtained within
human KCs (Fig. 2B). TLR agonists induced no significant TXB2
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Figure 4. Myd88-related pathways were essential for bacterial-induced
TXB2 increase. TLR-2 agonist (HKLM, 10 × 108 cells/mL) and microbial
lysates (K. pneumoniae, E. coli, E. cloacae, E. faecium, S. pneumoniae,
S. aureus, and C. albicans, 8 μg/mL for each lysate) were used to stimu-
late THP-1 cells and the expression of Myd88-related pathway proteins
were detected by Western blot: compared with the control group
(cells without any stimulates), the Myd88, phosphorus-MAPK/MAPK,
and phosphorus-NF-kB/NF-kB were significantly increased after
stimulation of HKLM or microbial lysates. The Gram-negative bacterial
lysates caused higher levels of phosphorus-MAPK and NF-kB than
Gram-positive bacteria or C. albicans. GAPDH was detected as loading
controls and each picture was representative from three separate
Western blot results.
increase in SECs (Fig. 2C). The previous publication also showed
that anaphylatoxin C5a significantly influenced the release of
TXA2 and PG in both KCs and HSCs, but not in SECs [25]. In
contrast, TLR agonists induced an overall reduction in HSCs and
TLR-3, -5, and -9 agonists even achieved significant decreases
(Fig. 2D). HSC can present bacterial antigens to NK T cells,
suppress the proliferation of T cells and activated HSC can also
inhibit its activation through a negative feedback loop [26, 27].
These immunosuppressive characteristics may also explain why
TLR agonists decreased TXB2 secretion in HSCs.
PG and TXA2 produced by NPCs in the liver play important
roles in increasing portal pressure following TLR activation [3,28].
Yet, only a few publications reported the functions of TLRs on
different NPCs. Our study was the first to investigate the com-
parison among mouse KCs, SECs, and HSCs after TLR agonists’
stimulation, also taking into account complex stimulation patterns
encountered with complex microbial extracts.
Cirrhosis can affect the function or phenotype of NPCs. In the
fibrotic liver, KCs overexpressed platelet-derived growth factor
(PDGF), which was the main factor that activates HSCs [29]. In
normal livers, most HSCs were in a quiescent condition, while
in cirrhotic livers, HSCs were activated by soluble factors (such
as PDGF), differentiated into myofibroblasts, and then produced
excess ECM [30]. Cirrhosis-induced SEC changes included a lack of
capillarization, SEC fenestration, and the formation of organized
basement membranes [31].
Endotoxin level and TLR expression were positively correlated
with the degree of liver fibrosis in patients, which may be impor-
tant factors that cirrhosis affected in NPCs [32]. Human primary
cells were rarely involved in the study of cirrhosis on NPCs. In this
experiment, we obtained two human samples of liver cirrhosis,
one of which was moderate and the other was severely cirrhotic.
The number of KCs in the moderate cirrhotic samples was almost
the same as that in normal tissues, while the number of KCs from
the severe cirrhotic sample was very low (almost 1/4 or 1/3 of
normal tissues). KCs extracted from normal or cirrhotic samples
all responded to the stimulation of bacterial lysates, however,
the increased TXA2 level was lower in the severe cirrhotic
sample than in normal or moderate cirrhotic samples (data not
shown). Due to the limited number of NPCs from severe fibrosis
samples, the impact of cirrhosis on SEC and HSC needs further
investigations.
Antagonists of TLR-1, -2, and -4 were additionally added to
human KCs to investigate potential treatment options to reduce
the bacterial-induced TXB2 secretion. GNB (including K. pneu-
moniae, E. coli, and E. cloacae) induced TXB2 secretion could be
attenuated by all three kinds of antagonists (Fig. 3A–C). TLR-1 and
-2 antagonists decreased TXB2 secretion following GPB (including
E. faecium, S. pneumonia, and S. aureus) stimulation (Fig. 3D–F).
Besides TLR-1 and -2 antagonists, E. faecium and S. pneumonia
induced TXB2 production was also reduced by TLR-4 antagonist.
Previous studies have reported that GPB and LPS induce homology
and cross-tolerance in the secretion of TXB2 and TNF-α in human
macrophages and this effect is achieved through the MAPK-related
pathway [33]. The higher phosphorylation levels of MAPK and
NF-kB caused by GNB than GPB supported the relation and our
results further demonstrated that the cross-resistance of GPB may
be caused by TLR-2 (Fig. 4).
Inflammatory cytokines produced by KCs via MAPK related
pathway is an important mechanism defending microbial infec-
tions. Mab-mTLR2 attenuated the production of all cytokines
induced by GPB stimulation, supporting the pivotal role of TLR-
2 in this process (Fig. 5A–D). GNB increased more inflammatory
cytokines than GPB, while TLR-2 antagonist failed to reduce all
inflammatory cytokines significantly. LPS-induced TNF-α and IL-6
production were reported to be related to the Gαi-coupled and
Src tyrosine kinase-coupled signaling pathways, which may be
independent of Myd88 signaling and therefore cannot be affected
by TLR-2 antagonist [33] (Fig. 5C, D). IL-1β can induce cross-
tolerance to LPS-induced mediators and does not alter MAPK or
NF-κB activation, suggesting that LPS-induced IL-1β production
is not solely dependent on MAPK-related pathways [23]. That
may explain why only GNB increased IL-1β and IL-23 production
(Fig. 5E and F). The GNB-induced increase was attenuated by
the TLR-2 antagonist, suggesting a cross-talk between TLR-4 and
TLR-2 in IL-1β and IL-23 production. Previous studies have shown
that the effect of C. albicans stimulation is more sensitive to PI3K
inhibitors than the MAPK-related pathway [33]. TLR-2 was more
related to the MAPK pathways and that may be the reason why
TLR-2 antagonist failed to protect against C. albicans induced IL-6
secretion (Fig. 5C, D).
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Figure 5. Effect of TLR-2 antagonist in the secretion of inflammatory cytokines. The inflammatory cytokines in the supernatants of human KCs
were measured by cytometric bead array after 24 h stimulation with TLR-2 agonist (HKLM, 10 × 108 cells/mL) or microbial lysates (K. pneumoniae, E.
coli, E. cloacae, E. faecium, S. pneumoniae, S. aureus, and C. albicans, 8 μg/mL for each lysates). (A–D) Both Gram-negative bacteria (K. pneumoniae, E. coli,
and E. cloacae) and Gram-positive bacteria (E. faecium, S. pneumoniae, and S. aureus) significantly (*p < 0.05, **p < 0.01, ***p < 0.001, comparing with
the control group, two-sided Student’s t-test) increased IL-10, IP-10, TNF-α, and IL-6 in human KCs after 24 h of stimulation. The TLR-2 antagonist
attenuated all the cytokines increases caused by Gram-positive bacteria as well as the TNF-α and IL-6 secretion evoked by Gram-negative bacteria
(#p < 0.05, ##p < 0.01, ###p < 0.001, comparing between vehicle and Mab-mTLR2 treatments, two-sided Student’s t-test). C. albicans only induced
TNF-α and IL-6 secretion (*p < 0.05) and TNF-α’ increase can be blocked by Mab-mTLR2 (#p < 0.05). (E and F) Gram-negative bacterial stimulation
also increased IL-1β and IL-23 (*p < 0.05, **p < 0.01, comparing with the control group, two-sided Student’s t-test), which can be reduced by TLR-2
antagonist (#p < 0.05 comparing between vehicle and Mab-mTLR2 treatments, two-sided Student’s t-test). (G and H) None of the microbial lysates
had significant effects on IL-1RA or IL-12p70. Data are expressed as mean ± SD, n = 5 samples, and are from three independent experiments with
a total of three human tissues.
Comparing the effects of TLR-1, -2, -4, and P2 × 7R antag-
onists, only TLR-2 antagonist reduced C. albicans-induced TXB2
increase (Fig. 3 and Supporting Information Fig. S4), this result
was in accordance with previous investigations that TLR-2 but not
TLR-4 was involved in the Candida mannan induced IL-17 produc-
tion in macrophages [34]. Despite a rare condition, positive fungal
cultures were found to be associated with significantly higher mor-
tality in patients with SBP [2]. Lack of specific indicators and low
culture success rates often lead to delayed diagnosis and treat-
ment of concomitant fungal infection in SBP patients. The effects
of TLR-2 antagonists in our experiments suggested TLR-2 as a
potential marker and an effective treatment for fungal infections.
Resistant organisms are increasingly recognized as an emerg-
ing problem worldwide due to the widespread use of antibiotics
in SBP [1,28]. Antibodies targeting TLRs may represent an attrac-
tive therapeutic option. OPN-305, the first humanized IgG4 mon-
oclonal antibody against TLR-2 on monocytes, was tested in a
randomized, double-blind, in-human phase I study [35]. In animal
models, TAK242 pretreatment attenuated inflammation-mediated
stress response and improved chronic pancreatitis and islet trans-
plantation results [36]. Our results also support the combined use
of TLR-2 and -4 antagonists in severely infected patients (Support-
ing Information Fig. S3).
There were some limitations in our experiments: the effect of
cirrhosis on NPCs has not been well investigated due to the limited
number of cells from severe cirrhosis samples; the results of in vitro
experiments lack the validation of in vivo animal experiments. We
have rat animal models for measuring portal vein pressure, but
this technique does not apply to mice. Further improvements to
this technique or new animal models may provide new evidence
for our results.
Different microbial lysates induced KCs to secrete TXA2 and
inflammatory factors using the same route: activation of TLR-2
leading to factor secretion. Therefore, TLR-2 may be a potential
marker and an attractive target for future treatment of patients
with SBP and ACLF. In addition to the common pathway via TLR-
2, GPB-products and GNB-products can be differentiated by the
inflammatory cytokines IL-23 and IL-1β. This might serve as a
novel basis to distinguish early between Gram-positive and Gram-
negative infections.
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Materials and methods
Animal and human tissue studies
Human liver tissue was provided by the Biobank of the
Department of General, Visceral and Transplantation Surgery,
Ludwig-Maximilians University (LMU), Munich, Germany under
the administration of the Human Tissue and Cell Research
(HTCR) Foundation. The framework of HTCR Foundation, which
includes obtaining written informed consent from all donors,
has been approved by the ethics committee of the Faculty of
Medicine at the LMU (approval number 025-12) as well as the
Bavarian State Medical Association (approval number 11142),
Germany. A total of 22 normal liver tissue samples were involved
in our experiments. The diagnosis of patient donors included liver
metastasis from digestive tract tumor (n = 16), hepatocellular
carcinoma (n = 5) and liver focal nodular hyperplasia (n = 1).
For animal experiments, only 6–8 weeks old male WT mice
(C57BL/6 background, 16–22 g) were selected for the present
study. All mice were adapted to the new environment for 1 week
before the experiments. They were housed in a pathogen-free facil-
ity and handled in accordance with standard use protocols, animal
welfare regulations, and the institutional guidelines. All animals
and human tissues were ethically treated according to the criteria
prepared by the National Academy of Sciences and published by
the National Institutes of Health in addition to the legal require-
ments in Germany. All experiments were approved by the local
government (Regierung von Oberbayern, Munich, Germany) and
were reported to the responsible authorities annually.
Isolation of primary liver nonparenchymal cells
The isolation of NPCs was performed according to published pro-
tocols [4,37,38]. Briefly, liver tissues from mice and humans were
cut into 5–10 mm thick slices and digested for 20 min at 37°C
with pronase (Sigma Chemical Co, St. Louis, USA) and DNase
(Roche, Mannheim, Germany). After filtration and centrifugation,
the pellets were resuspended in GBSS and layered over fresh
Nycodenz gradients (16.7% for KCs and 28.7% for HSCs, Axxis
Shield, Rodelokka, Norway). The mixtures were centrifuged at
room temperature without brake. The interfaces were collected
after centrifugation and then centrifuged with brake. For isolation
of SECs, Anti-SEC CD146 MicroBeads (Miltenyi Biotec, Germany)
were added in the resuspended cells (107 cells/mL) for immuno-
labeling. After incubation, SECs were separated with magneti-
cally activated cell sorting system MACS (Miltenyi Biotec, Ger-
many). NPCs were collected and resuspended in RPMI 1640 sup-
plemented with L-glutamine, FCS (PAA, Cölbe, Germany), and
streptomycin/penicillin (Sigma, St. Louis, USA). The medium was
changed after 6 h to remove non-adherent cells (such as erythro-
cyte). Cells were seeded in six-well plates and cultured at 37°C in
5% CO2. Before stimulation, the medium was changed to RPMI
1640 without FCS or antibiotics for 24 h.
Cell culture line and treatment
THP-1 monocytic cells (American Type Culture Collection, ATCC
reference number TIB-202TM) were a kind gift from Prof. Peter
Nelson. Cells were cultured in RPMI 1640 medium supplemented
with 10% FCS, L-glutamine and streptomycin/penicillin at 37°C
in 5% CO2. THP-1 monocytes were seeded in six-well plates and
differentiated to macrophages by 24 h stimulation with 20 ng/mL
PMA (Sigma, St. Louis, USA). After incubation, adherent cells were
washed three times with PBS and incubated with fresh RPMI 1640
medium without PMA [39]. Before stimulation, the medium was
changed to RPMI 1640 without FCS or antibiotics for 24 h.
In vitro stimulation plan
The following microbes were isolated from patients with SBP:
K. pneumoniae, E. coli, E. cloacae, E. faecium, S. pneumoniae,
S. aureus, and C. albicans. The isolates were cultured on Columbia
5% sheep blood media (Becton Dickinson, Heidelberg, Germany)
at 37°C under aeration. After growth, the lysates were collected
by centrifugation and resuspended in a small volume of PBS
and subsequently heat-inactivated. All extracts were found to be
sterile and were measured for protein content using the Bradford
technique. Extracts were diluted to achieve standardized protein
concentrations. After 24 h of stimulation, the supernatants of
cells were collected and stored at -80°C before use. In some
experiments, the special agonists or antagonists were used to
treat cells (Supporting Information Table S1).
Western blot analysis
Cells were lysed in lysis buffer (RIPA-buffer supplemented with
protease inhibitors) on ice, the proteins were collected by centrifu-
gation. After measuring the protein concentration by BCA protein
assay kit (Thermo Scientific). The cells were boiled with a suit-
able volume of loading buffer (Sigma). The samples and marker
were loaded onto the appropriate concentration of SDS-PAGE gels
and transferred onto polyvinylidene difluoride membrane with the
Mini-PROTEAN R© System (Bio-Rad, USA). The membranes were
then incubated overnight at 4°C with primary antibody after block-
ing: anti-Myd88, MAPK, pMAPK, NF-kB, or p-NFkB antibodies
(1:1000, Cell Signaling Technology); GAPDH antibody (1:1000,
Sigma). Membranes were washed and then incubated with the
secondary antibody (Sigma) for 1 h at room temperature. The
activity was visualized by chemiluminescence: the working solu-
tion (SuperSignalTM West Femto, Thermo Fisher) was added on
membranes and then the blot was exposed by the imaging system
(CHEMOCAM Imager 3.2, INTAS, Germany).
ELISA measurement
TXA2 is not a cyclic hormone and works within a short distance of
its biosynthesis, it is rapidly hydrolyzed to TXB2 after synthesis and
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released into the circulation. As a result, TXB2, the stable degrada-
tion product of TXA2, was measured from the supernatants of the
stimulated cells by TXB2 ELISA kit (Cayman Chemical, Ann Arbor,
MI, USA). Supernatant samples were stored at -80°C until mea-
surement. The procedures were well described in our publications
before [4,16].
Cytometric bead array
Inflammatory-related factors, including TNF-α, IL-1β, IL-1RA, IL-6,
IL-10, IL-12p70, IL-23, and C-X-C motif chemokine 10 (CXCL-10),
were evaluated in the supernatant of human KCs using Cytometric
bead array (CBA) method with LEGENDplexTM Human M1/M2
Macrophage Panel (BioLegend, San Diego, CA, USA) according
to the manufacturer’s instructions. Methods were adhered to the
guidelines of published articles [40]. A BDTM FACS Canto II flow
cytometer was used to collect the data. The data were analyzed
with the LEGENDplex software.
Confocal microscopy
Primary antibodies against CD163 (1:100; Acris, Sunnyvale,
CA, USA), CD68 (1:100; Dako, Santa Clara, CA, USA), and
CD11b (1:100; Santa Cruz, Dallas, Texas, USA) were used for
immunofluorescence. The cells were fixed with 4% paraformalde-
hyde (Roth, Karlsruhe, Germany) in PBS for 15 min, then,
washed with PBS three times and incubated with blocking buffer
for 30 min at 37°C. Cells were generally stained with primary
antibody overnight at 4°C. After additional washing steps with
PBS, fluorescent-labeled secondary antibodies (Life Technolo-
gies GmbH, Darmstadt, Germany) were added. The cells were
analyzed by confocal microscopy (Zeiss LSM 510 META, Jena,
Germany).
Statistical analysis
All data were presented as the mean ± SD. All samples were
randomly distributed to different groups. The two-sided Students
t-test was used for paired or unpaired observations. One-way
ANOVA was used when needed. A value of p < 0.05 was con-
sidered to be statistically significant; n denotes the number of
samples used. SPSS and Graphpad were used for data analysis
and figure drawing.
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